TD Private Client Wealth’s Tvardi Therapeutics TVRD Stock Holding History

TD Private Client Wealth’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-149	Closed	-$283	–	1860
2026 Q2	$283	Buy	+149	New	+$467	﹤0.01%	1619

Other funds holding TVRD

Brookstone Capital Management Wheaton, Illinois $10.1B AUM 17.94% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

TD Private Client Wealth's TVRD Position: Q3 2026 in Review

TD Private Client Wealth sold out of Tvardi Therapeutics (TVRD) in Q3 2026, closing a stake of 149 shares — an estimated $283 sold.

TD Private Client Wealth first reported a position in TVRD in Q2 2026 and held it in 1 quarter. The position peaked at $283 in Q2 2026. 5 funds tracked by Wall St. Rank hold TVRD as of Q3 2026.

TD Private Client Wealth reported no remaining Tvardi Therapeutics position as of Q3 2026 after selling out during the quarter.
TD Private Client Wealth sold 149 Tvardi Therapeutics shares in Q3 2026, an estimated $283.
TD Private Client Wealth first reported a position in Tvardi Therapeutics in Q2 2026 and held it in 1 quarter.
TD Private Client Wealth's Tvardi Therapeutics position peaked at $283 in Q2 2026.
5 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.